AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05309525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase Clostridium Histolyticum-Aaes
Description: subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple).
Study NCT05309525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lysteda 650 MG Oral Tablet
Description: Subjects will be given the therapeutic dose of tranexamic acid for menorrhagia, which is 1300 mg PO TID for up to 5 days during menstruation
Study NCT06323174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide
Description: Participants will receive once-weekly cagrilintide subcutaneously.
Study NCT06323174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will receive once-weekly semaglutide subcutaneously.
Study NCT06323174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
Study NCT06361537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCTA-C1-INH
Description: OCTA-C1-INH is a stable, sterile, virus-inactivated, nano-filtered, highly purified concentrate of human C1-INH prepared from pooled human plasma. After reconstitution in 2.5mL water for injection, the solution can be administered as a slow IV injection. OCTA-C1-INH is given as a dose of 20 IU/kg body weight (BW)
Study NCT06361537 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1 mL/kg BW 0.9% sodium chloride injection
Study NCT05985135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Biopsy
Description: Needle muscle biopsy of the outer thigh muscle
Study NCT05985135 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Muscle Biopsy
Description: Needle muscle biopsy of the outer thigh muscle
Study NCT05985135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jell-O with Amino acids
Description: An amino acid mixture containing 13C6 Lysine isotope label
Study NCT05985135 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Jell-O with Amino acids
Description: An amino acid mixture containing 13C6 Lysine isotope label
Study NCT05985135 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Intravenous form of sugar
Study NCT06641908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3554
Description: M3554 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose is determined in participants with STS (dose escalation A) and glioblastoma and IDH wildtype (dose escalation B).
Study NCT04234022 — intervention group
Intervention type: DRUG
Intervention: Zn-DDC
Description: Zn-DDC added to myeloma samples for culturing
Study NCT05714982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label with text health warning
Description: Labels with e-cigarette health warning that include text about health harms of vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
Study NCT05714982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label with pictorial health warning
Description: Labels with e-cigarette health warning that include the same text about health harms of vaping and corresponding pictorial images will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
Study NCT05207046 — intervention group
Intervention type: OTHER
Intervention: Mechanical Ventilation
Description: Patients will be assessed and measurements will be taken during controlled ventilation (most likely \<72 hours of ICU admission), during partially assisted ventilation, and until spontaneous unassisted breathing is reached.
Study NCT06554353 — intervention group
Intervention type: DEVICE
Intervention: Oscillometer
Description: The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
Study NCT04707313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Cohorts 1 and 2)
Description: 4 matching placebo tablets taken twice daily
Study NCT04707313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 (Cohorts 1 and 2)
Description: Participants will be randomized to one of 5 active target dose levels (40, 80, 120, 160 or 200 mg BID) achieved through 1-week titration steps, or 3 active target dose levels (120, 160 or 200 mg BID) achieved through 2-week titration steps, taking 4 tablets twice daily
Study NCT04707313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Cohort 3)
Description: 2 matching placebo tablets taken twice daily
Study NCT04707313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 (Cohort 3)
Description: Participants will be randomized to one of 3 active target dose levels (80, 140 or 200 mg BID) achieved through 4-week titration steps, taking 2 tablets twice daily.
Study NCT04187326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial Microexpression Training
Description: The METT is a well-validated task designed to improve perception of subtle changes in facial expressions, termed microexpressions. Participants with high trait anxiety will return to the lab approximately six months post scan visit to complete this computer-based task. They will receive feedback during the task on their accuracy.
Study NCT06482554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumateperone 42 mg
Description: Standard treatment with lumateperone
Study NCT06482554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone 2 mg
Description: Standard treatment with other antipsychotic drugs
Study NCT05714982 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Label with neutral statements about vaping
Description: Labels with neutral statements about vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 statements based on their assigned trial arm; at Visit 3, they will get 2 additional statements based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
Study NCT04982796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: See description of psilocybin-enhanced psychotherapy arm.
Study NCT04982796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment-as-usual
Description: See description of treatment-as-usual arm.
Study NCT04982796 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment-as-usual
Description: See description of treatment-as-usual arm.
Study NCT05677633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
Study NCT05746325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Photography
Description: Digital photographs taken of array placement
Study NCT05746325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo LP
Study NCT05746325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05024084 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Sevoflurane
Description: Sevoflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min
Study NCT05024084 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Desflurane
Description: Desflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min
Study NCT04955288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aortic balloon assisted resuscitation
Description: On the basis of the traditional resuscitation mode, the aortic balloon occlusion technology is used, that is, at the same time when the cardiopulmonary resuscitation starts, the aortic balloon catheter is quickly punctured to the distal end of the aortic zone I (septum level) through ultrasound assistance, and then Continue to inflate the balloon to block the aortic blood flow until the end of the cardiopulmonary resuscitation to deflate the balloon and remove the balloon catheter.
Study NCT04955288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional cardiopulmonary resuscitation
Description: Use the traditional manual chest compression mode, that is, refer to the latest version of the CPR Guidelines.~Artificial chest compressions are performed under the monitoring of the pressure quality feedback device to ensure that the compression depth is 5-6cm, the frequency is 100-120 times/min, the compression position is fixed, and the chest wall fully rebounds.
Study NCT04955288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal cooling
Description: The new transesophageal cooling method is adopted, that is, the esophageal cooling catheter is indwelled after resuscitation in patients with cardiac arrest, and then connected to a small temperature-controlled water circulation system to continuously infuse 4℃ cold water. After the patient's body temperature reaches the target temperature of 33℃, the temperature-controlled water circulation system is adjusted Maintain the target body temperature of (33±0.5)°C for 24 hours, and then rewarm to (37±0.5)°C normal body temperature at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
Study NCT04955288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional cooling
Description: The traditional body surface ice blanket cooling method is adopted, that is, the patient with cardiac arrest lies on the temperature control blanket after resuscitation, and then uses the ice blanket host to continuously infuse the temperature control blanket with 4℃ cold water, and wait until the patient's body temperature reaches the target temperature of 33℃. The temperature of the circulating water is controlled by adjusting the ice blanket host to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to the normal body temperature of (37±0.5)°C at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
Study NCT05746325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Transducer arrays applied and wear NovoTTF-200T
Study NCT04873024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cMAP Flow V 2.0
Description: Breathing data collected by the device will be processed by a machine learning algorithm to predict obstructive apnea events. When obstructive apnea events are predicted, the algorithm triggers the CPAP device to respond to the apnea event ahead of its onset.~For the control treatment, the device will operate as its conventional treatment.
Study NCT05062577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8062
Description: oral
Study NCT05062577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ASP8062
Description: oral
Study NCT05062577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: sublingual
Study NCT05062577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: buprenorphine/naloxone
Description: sublingual
Study NCT05495334 — intervention group
Intervention type: PROCEDURE
Intervention: Treatment for Knee OA
Description: Pain management treatment for knee OA.
Study NCT04234022 — intervention group
Intervention type: DRUG
Intervention: Lanalidomide with Zn-DDC
Description: Lanalidomide with Zn-DDC added to myeloma samples for culturing
Study NCT05746247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Testing centralized referral mechanism for PCPs
Description: For patients with a Penn PCP, we are testing a centralized referral mechanism to increase the number of referrals to preventive cardiology (default/opt out referrals)~For default/opt out: PCPs will receive a pended order for a referral for their patient to see a lipid specialist for a formal FH evaluation. Not interacting with the pended order or accepting the pended order will indicate that the referral to a lipid specialist should be placed.
Study NCT05746247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inviting patients to complete a telehealth appointment with a lipid specialist for an FH evaluation
Description: All eligible patients will be informed that they have been identified by the FIND FH tool as potentially having familial hypercholesterolemia. All patients will be invited to schedule a telehealth appointment with a lipid specialist for a formal evaluation for FH.
Study NCT04234022 — intervention group
Intervention type: DRUG
Intervention: Pomalidomide with Zn-DDC
Description: Lanalidomide with Zn-DDC added to myeloma samples for culturing
Study NCT05219617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to \< 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID \[or a total of 400 mg per day\]).~Subjects 4 to \< 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID \[or a total of 600 mg per day\]).
Study NCT05219617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carisbamate
Description: Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to \< 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID \[or a total of 400 mg per day\]).~Subjects 4 to \< 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID \[or a total of 600 mg per day\]).
Study NCT04961814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liberal fasting
Description: preoperative fasting according to 6-4-0 regimen then qualitative and quantitative preoperative gastric ultrasound assessment will be done to evaluate the proportion of patients with risky stomach
Study NCT04961814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard fasting
Description: preoperative fasting according to 6-4-2 regimen then qualitative and quantitative preoperative gastric ultrasound assessment will be done to evaluate the proportion of patients with risky stomach
Study NCT05609032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sense2Quit App
Description: Participants in the intervention arm will receive access to Sense2Quit, a smartphone app that links to a smartwatch.
Study NCT04661150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 3 cycles prior to surgery and 5 cycles after surgery.
Study NCT04661150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as an 8 mg/kg IV loading dose and then 6 mg/kg IV on Day 1 of a 21-day cycle for 3 cycles before surgery, and administration will continue after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
Study NCT04661150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be administered as an 8 mg/kg IV loading dose and then 6 mg/kg IV on Day 1 of a 21-day cycle for 3 cycles before surgery, and administration will continue after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
Study NCT04661150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 will be administered twice orally on Days 1-14, repeated every 3 weeks.
Study NCT04661150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 will be administered twice orally on Days 1-14, repeated every 3 weeks.
Study NCT04661150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m\^2 will be administered by IV on Day 1 of a 21-day cycle.
Study NCT04661150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m\^2 will be administered by IV on Day 1 of a 21-day cycle.
Study NCT05632731 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: double cleavage-stage or single blastocyst stage embryos transfer
Description: Infertile women requesting in vitro fertilization treatment were randomly assigned to undergo transfer of either two cleavage-stage embryos or a single blastocyst-stage embryo.
Study NCT06240689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is administered intravenously on the first day of each cycle. 21 days per cycle.
Study NCT06240689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered intravenously on the first day of each cycle. 21 days per cycle.
Study NCT05424614 — intervention group
Intervention type: OTHER
Intervention: Functional outcome follow-up of patients
Description: Patients were followed up by telephone after discharge, every 4 weeks, until the end of the 3-month follow-up. Their functional status was determined based on the MRS score (modified Rankin Scale). Those with less than 3 points were defined as having a good prognosis, and those with more than 3 points were defined as having a poor prognosis
Study NCT06444113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatunumab
Description: No study-treatment is provided for this study. Study participants will be treated with commercially available ofatumumab according to the local label.
Study NCT05016934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A vaccine composed of a recombinant S1 antigen
Description: Two applications of three different doses of a vaccine composed of a recombinant S1 antigen, a subunit of SARS-CoV-2 virus S protein
Study NCT05016934 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: A vaccine composed of a recombinant S1 antigen
Description: Two applications of three different doses of a vaccine composed of a recombinant S1 antigen, a subunit of SARS-CoV-2 virus S protein
Study NCT04518137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle
Description: 48 patients enrolled will be treated with 30mg QD of ATG-008, orally, each 4 week (28-day) a cycle
Study NCT05017558 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: point of care
Description: HIV-1 infected women will benefit from a viral load measurement by POC (Cepheid GenXpert HIV-1 viral load) at the time of delivery.~Newborns will benefit :~1. Antiretroviral preventive treatment differentiated according to their risk of infection in accordance with national recommendations:~   * High risk (maternal VL ≥1000 cp/ml): AZT/NVP for 12 weeks.~  * Low risk (maternal VL \<1000 cp/ml): NVP for 6 weeks.~2. virological screening for HIV by qualitative POC (Cepheid GenXpert HIV-1 qual) from birth (for high-risk newborns) at 6 weeks, at 9 months and at any time in the event of clinical manifestations suggestive of HIV infection.~3. In the event of a positive HIV test, the child will initiate immediately AZT/3TC/LPV/r~4. support from volunteers to improve retention in care, promotion of exclusive breastfeeding and family nutritional support
Study NCT06341894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: CDK4/6 inhibitor dalpiciclib, 100mg orally qd
Study NCT06341894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Fulvestrant/AI
Study NCT05124730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500mg prolonged release tablets (JSC Farmak, Ukraine)
Description: One tablet of the Test product was administered orally with 240 mL of water.
Study NCT05124730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)
Description: One tablet of Reference (R) Product was administered orally with 240 mL of water.
Study NCT05136170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenegermin
Description: Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID) for 28 consecutive days.
Study NCT05136170 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle was instilled with the same scheme of the test product
Study NCT06544915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Synbiotic, Probiotic, Placebo
Description: Use of dietary supplements to improve gut microbiome and cardiometabolic health